JP2010077136A - 新規免疫修飾性タンパク質およびその有用な態様 - Google Patents
新規免疫修飾性タンパク質およびその有用な態様 Download PDFInfo
- Publication number
- JP2010077136A JP2010077136A JP2009249633A JP2009249633A JP2010077136A JP 2010077136 A JP2010077136 A JP 2010077136A JP 2009249633 A JP2009249633 A JP 2009249633A JP 2009249633 A JP2009249633 A JP 2009249633A JP 2010077136 A JP2010077136 A JP 2010077136A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition
- protein
- yci
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 61
- 102000004169 proteins and genes Human genes 0.000 title claims description 58
- 230000002519 immonomodulatory effect Effects 0.000 title claims description 6
- 238000000034 method Methods 0.000 claims abstract description 32
- 241001536558 Yaba monkey tumor virus Species 0.000 claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 82
- 108020004707 nucleic acids Proteins 0.000 claims description 56
- 102000039446 nucleic acids Human genes 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 31
- 102000004127 Cytokines Human genes 0.000 claims description 30
- 108090000695 Cytokines Proteins 0.000 claims description 30
- 102000019034 Chemokines Human genes 0.000 claims description 20
- 108010012236 Chemokines Proteins 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 16
- 241000700574 Yatapoxvirus Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 14
- 102000009410 Chemokine receptor Human genes 0.000 claims description 13
- 108050000299 Chemokine receptor Proteins 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 238000013518 transcription Methods 0.000 claims description 7
- 238000013519 translation Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 201000008383 nephritis Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 230000005784 autoimmunity Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 206010051113 Arterial restenosis Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000009285 allergic inflammation Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000004481 post-translational protein modification Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 206010011086 Coronary artery occlusion Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 238000001727 in vivo Methods 0.000 abstract description 7
- 108010067390 Viral Proteins Proteins 0.000 abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000003248 secreting effect Effects 0.000 abstract 3
- 230000008975 immunomodulatory function Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 18
- 102000003810 Interleukin-18 Human genes 0.000 description 8
- 108090000171 Interleukin-18 Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000004853 protein function Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000015872 Gaucher disease Diseases 0.000 description 2
- -1 IL -4 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108091005461 Nucleic proteins Chemical group 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000700628 Chordopoxvirinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000700572 Entomopoxvirinae Species 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000700560 Molluscum contagiosum virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700562 Myxoma virus Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000172105 Yata virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000023247 mammary gland development Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Abstract
【解決手段】ウイルスタンパク質としては、ポックスウイルスファミリー、すなわちヤバサル腫瘍ウイルスのゲノムから分泌型ウイルスタンパク質単離する。それを用いての疾患の治療において、インビボで投与する場合に抗炎症性およウイルスタンパク質び/または免疫修飾性の役割を媒介することができる、従って、炎症及び自己免疫疾患等の治療に用いることが出来る。
【選択図】なし
Description
(1)SEQ ID NO: 1に提供される核酸配列の短縮型、アナログおよびホモログ;
(2)TをUに置換することによりSEQ ID NO: 1とは異なる核酸配列;
(3)SEQ ID NO: 1の全長に相補的な核酸配列またはそれに由来する核酸フラグメントに対して相補的な核酸配列;
(4)SEQ ID NO: 1中に示される核酸配列とハイブリダイズする核酸配列;
(5)遺伝コードの縮重によりSEQ ID NO: 1の全長と異なる核酸配列;
が含まれる。
Claims (49)
- ヤバサル腫瘍ウイルス(Yaba Monkey Tumor Virus)に由来する、(i)SEQ ID NO: 1により定義された、精製された核酸分子、およびそのフラグメント、ホモログおよびそれらのアナログ。
- (i)SEQ ID NO: 1に記載の配列に対して相補的な配列、またはそのフラグメント、アナログおよびホモログ、を含む、請求項1に記載の核酸分子。
- 請求項1に示す配列を含む核酸分子であって、それぞれのTがUにより置換されていてもよい、前記核酸分子。
- 請求項1に記載の核酸配列をコードする、1またはそれ以上の核酸配列を含有する、組換え核酸ベクター。
- 請求項1に記載の核酸配列、またはそのフラグメント、アナログおよびホモログを含有する、宿主細胞。
- 宿主細胞が真核細胞である、請求項5に記載の宿主細胞。
- 宿主細胞が原核細胞である、請求項5に記載の宿主細胞。
- 請求項1において示される核酸配列、またはそのフラグメント、アナログおよびホモログによりコードされるか、またはSEQ ID NO: 2によりコードされる、タンパク質分子。
- 請求項8に記載のタンパク質分子のエピトープに対する特異性を有する、抗体分子またはそのフラグメント。
- タンパク質または非-タンパク質ベース部分と結合されている、請求項8に記載のタンパク質分子。
- 前記抗体がタンパク質および/または非-タンパク質部分により標識される、請求項9に記載の抗体分子またはそのフラグメント。
- 請求項1に記載の1またはそれ以上の核酸配列の発現を介して、ケモカイン機能をモジュレートする方法。
- 前記タンパク質が非-共有的に1またはそれ以上の哺乳動物ケモカインと結合する、請求項8における前記タンパク質間の相互作用を介して、ケモカイン機能をモジュレートする方法。
- 請求項1に記載の1またはそれ以上の核酸配列の発現を介して、サイトカイン機能をモジュレートする方法。
- 前記タンパク質が非-共有的に1またはそれ以上の哺乳動物サイトカインと結合する、請求項8に記載の前記タンパク質間の相互作用を介して、サイトカイン機能をモジュレートする方法。
- 請求項1に記載の1またはそれ以上の核酸配列の発現を介して、ケモカイン受容体機能をモジュレートする方法。
- 前記タンパク質が非-共有的に1またはそれ以上の哺乳動物ケモカイン受容体と結合する、請求項8における前記タンパク質間の相互作用を介して、ケモカイン受容体機能をモジュレートする方法。
- 請求項1に記載のものの中でコードされるタンパク質分子と結合することができる物質を、同定する方法。
- 請求項1に記載のものの中でコードされる本明細書中の核酸の転写をモジュレートする剤を同定する方法。
- 請求項8に記載のもの由来の1または複数のタンパク質の翻訳をモジュレートする剤を同定する方法。
- 請求項8に記載のもの由来の1または複数のタンパク質の後-翻訳修飾をモジュレートする剤を同定する方法。
- 哺乳動物生体中の炎症を治療するための、請求項1に記載の核酸からなる組成物。
- 哺乳動物生体中の炎症を治療するための、請求項8に記載の1または複数のタンパク質を含む組成物。
- 炎症により媒介されるヒト症状を治療するための、請求項1に記載の核酸を含む組成物。
- 炎症により媒介されるヒト症状を治療するための、請求項8に記載の1または複数のタンパク質を含む組成物。
- 自己免疫により媒介されるヒト症状を治療するための、請求項1に記載の核酸を含む組成物。
- 自己免疫により媒介されるヒト症状を治療するための、請求項8に記載の1または複数のタンパク質を含む組成物。
- 炎症と関連するヒト症状を予防するための、請求項1に記載の核酸を含む組成物。
- 炎症と関連するヒト症状を予防するための、請求項8に記載の1または複数のタンパク質を含む組成物。
- 自己免疫と関連するヒト症状を予防するための、請求項1に記載の核酸を含む組成物。
- 自己免疫と関連するヒト症状を予防するための、請求項8に記載の1または複数のタンパク質を含む組成物。
- 前記症状が:
(i) アレルギー性炎症;または
(ii) 喘息;または
(iii) 乾癬;または
(iv) 糖尿病;または
(v) 慢性関節リウマチ;または
(vi) 多発性硬化症;または
(vii) エリテマトーデス;または
(viii) 移植拒絶;または
(ix) 移植片拒絶;または
(x) 腎炎;または
(xi) 動脈再狭窄;または
(xii) 冠動脈閉塞症;または
(xiii) 移植血管疾患;または
(xiv) アテローム性動脈硬化;または
(xv) 不安定型アテローム性動脈硬化性プラーク破裂;または
(xvi) 虚血再潅流損傷;または
(xvii) 腎炎
のいずれかである、ヒト症状を治療するための組成物。 - 前記症状が慢性的性質のものである、請求項32に記載の組成物。
- 前記症状が急性または亜急性の性質のものである、請求項32に記載の組成物。
- 免疫修飾性症状を有する哺乳動物に対して治療的有効量の請求項1または請求項8に記載の化合物を投与することを含み、前記化合物が前記哺乳動物において免疫修飾性作用を有する、前記免疫修飾性症状を有する哺乳動物を治療する方法。
- 症状が、アレルギー性炎症、喘息、乾癬、糖尿病、慢性関節リウマチ、多発性硬化症、エリテマトーデス、移植拒絶、移植片拒絶、腎炎、動脈再狭窄、冠動脈閉塞症、移植血管疾患、アテローム性動脈硬化、不安定型アテローム性動脈硬化性プラーク破裂、虚血再潅流損傷、腎炎、から選択される、請求項35に記載の方法。
- 実質的に純粋なヤタポックスウイルスサイトカイン阻害剤ポリペプチド。
- ヤタポックスウイルスサイトカイン阻害剤ポリペプチドをコードする、実質的に純粋なヤタポックスウイルス核酸分子。
- ゲノムDNA、cDNA、およびmRNAから選択される、請求項11に記載の核酸分子。
- 請求項1または請求項38に記載の核酸分子を含むベクター。
- 遺伝子治療ベクターである、請求項40に記載のベクター。
- 請求項40に記載のベクターを含む細胞。
- 前記核酸分子がヤタポックスウイルスサイトカイン阻害剤ポリペプチドの発現のための制御配列に対して機能可能に連結しており、そして前記制御配列がプロモーターを含む、請求項40に記載のベクター。
- 請求項1または請求項38に記載の核酸分子を含む、非-ヒトトランスジェニック動物。
- 請求項44に記載の非-ヒトトランスジェニック動物由来の細胞。
- ヤタポックスウイルスサイトカイン阻害剤ポリペプチドと実質的に同一なポリペプチドをコードする片方または両方のアリルにおいてノックアウト変異を有する非-ヒトトランスジェニック動物。
- ヤタポックスウイルス遺伝子またはヤタポックスウイルス遺伝子ホモログまたはそれらのフラグメントを解析するためのプローブであって、前記プローブがヤタポックスウイルスサイトカイン阻害剤ポリペプチドまたはそのフラグメントをコードする配列と少なくとも50%のヌクレオチド配列同一性を有し、前記ポリペプチドフラグメントが少なくとも6アミノ酸を含み、そして前記プローブが高ストリンジェントな条件下で、少なくともヤタポックスウイルス核酸分子の部分に対してハイブリダイズする、前記プローブ。
- 被検体中に存在するヤタポックスウイルス核酸分子を解析するための核酸分子プローブを含む、ヤタポックスウイルス核酸分子の解析用キット。
- 被検体中に存在するヤタポックスウイルスサイトカイン阻害剤ポリペプチドを解析するための抗体を含む、ヤタポックスウイルスサイトカイン阻害剤ポリペプチドを解析するためのキット。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25114700P | 2000-12-04 | 2000-12-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002547951A Division JP4472252B2 (ja) | 2000-12-04 | 2001-12-04 | 新規免疫修飾性タンパク質およびその有用な態様 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010077136A true JP2010077136A (ja) | 2010-04-08 |
Family
ID=22950675
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002547951A Expired - Fee Related JP4472252B2 (ja) | 2000-12-04 | 2001-12-04 | 新規免疫修飾性タンパク質およびその有用な態様 |
JP2009126008A Withdrawn JP2009227686A (ja) | 2000-12-04 | 2009-05-26 | 新規免疫修飾性タンパク質およびその有用な態様 |
JP2009249633A Pending JP2010077136A (ja) | 2000-12-04 | 2009-10-30 | 新規免疫修飾性タンパク質およびその有用な態様 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002547951A Expired - Fee Related JP4472252B2 (ja) | 2000-12-04 | 2001-12-04 | 新規免疫修飾性タンパク質およびその有用な態様 |
JP2009126008A Withdrawn JP2009227686A (ja) | 2000-12-04 | 2009-05-26 | 新規免疫修飾性タンパク質およびその有用な態様 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7101559B2 (ja) |
EP (1) | EP1339737B1 (ja) |
JP (3) | JP4472252B2 (ja) |
AT (1) | ATE364625T1 (ja) |
AU (2) | AU1572702A (ja) |
CA (1) | CA2428097A1 (ja) |
DE (1) | DE60128950T2 (ja) |
DK (1) | DK1339737T3 (ja) |
ES (1) | ES2287192T3 (ja) |
PT (1) | PT1339737E (ja) |
WO (1) | WO2002046214A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1331943A4 (en) | 2000-10-11 | 2005-01-26 | Viron Therapeutics Inc | NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION |
CA2428097A1 (en) | 2000-12-04 | 2002-06-13 | Viron Therapeutics, Inc. | Immunomodulatory protein derived from the yaba monkey tumor virus |
US7718368B2 (en) | 2000-12-04 | 2010-05-18 | Viron Therapeutics Inc. | Immunomodulatory protein and useful embodiments thereof |
US8251876B2 (en) | 2008-04-22 | 2012-08-28 | Hill-Rom Services, Inc. | Breathing exercise apparatus |
US9180271B2 (en) | 2012-03-05 | 2015-11-10 | Hill-Rom Services Pte. Ltd. | Respiratory therapy device having standard and oscillatory PEP with nebulizer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000511535A (ja) * | 1996-05-22 | 2000-09-05 | ユニバーシティー オブ アルベルタ | 2型ケモカイン結合蛋白質およびそれらの使用方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US38203A (en) * | 1863-04-14 | Improved strike for door-locks | ||
US5651972A (en) * | 1989-04-21 | 1997-07-29 | University Of Florida Research Foundation, Inc. | Use of recombinant swine poxvirus as a live vaccine vector |
JPH05502037A (ja) | 1990-04-24 | 1993-04-15 | シェリング・コーポレーション | 可溶性のトランケートされたガンマ―インターフェロン受容体 |
DE69130262T2 (de) | 1991-03-29 | 1999-03-18 | Immunex Corp., Seattle, Wash. | Isolierte virale proteine als cytokinantagonisten |
WO1995027503A1 (en) | 1994-04-08 | 1995-10-19 | Mcfadden D Grant | Antirestenosis protein |
US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
US5939525A (en) | 1995-03-27 | 1999-08-17 | Viron Therapeutics, Inc. | Methods of treating inflammation and compositions therefor |
US6495515B1 (en) | 1995-04-19 | 2002-12-17 | Viron Therapeutics, Inc. | Chemokine binding protein and methods of use therefor |
ATE243526T1 (de) | 1995-04-19 | 2003-07-15 | Robarts John P Res Inst | Chemokin bindendes protein und verfahren zu seiner verwendung |
KR19990063653A (ko) | 1995-09-29 | 1999-07-26 | 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 | 케모킨 억제제 |
EP1034789A1 (en) * | 1996-05-22 | 2000-09-13 | University Of Alberta | Type-2 chemokine binding proteins and methods of use therefor |
CA2340579A1 (en) * | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
US6589933B1 (en) | 1999-04-02 | 2003-07-08 | Viron Therapeutics, Inc. | Myxoma chemokine binding protein |
AU2001240109A1 (en) | 2000-03-07 | 2001-09-17 | U.S. Army Medical Research Institute Of Infectious Diseases | Dna vaccines against poxviruses |
EP1331943A4 (en) | 2000-10-11 | 2005-01-26 | Viron Therapeutics Inc | NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION |
CA2428097A1 (en) | 2000-12-04 | 2002-06-13 | Viron Therapeutics, Inc. | Immunomodulatory protein derived from the yaba monkey tumor virus |
-
2001
- 2001-12-04 CA CA002428097A patent/CA2428097A1/en not_active Abandoned
- 2001-12-04 ES ES01999573T patent/ES2287192T3/es not_active Expired - Lifetime
- 2001-12-04 JP JP2002547951A patent/JP4472252B2/ja not_active Expired - Fee Related
- 2001-12-04 AU AU1572702A patent/AU1572702A/xx active Pending
- 2001-12-04 AU AU2002215727A patent/AU2002215727B8/en not_active Ceased
- 2001-12-04 PT PT01999573T patent/PT1339737E/pt unknown
- 2001-12-04 EP EP01999573A patent/EP1339737B1/en not_active Expired - Lifetime
- 2001-12-04 DK DK01999573T patent/DK1339737T3/da active
- 2001-12-04 WO PCT/CA2001/001734 patent/WO2002046214A2/en active IP Right Grant
- 2001-12-04 AT AT01999573T patent/ATE364625T1/de active
- 2001-12-04 DE DE60128950T patent/DE60128950T2/de not_active Expired - Lifetime
-
2003
- 2003-06-04 US US10/455,000 patent/US7101559B2/en not_active Expired - Fee Related
-
2009
- 2009-05-26 JP JP2009126008A patent/JP2009227686A/ja not_active Withdrawn
- 2009-10-30 JP JP2009249633A patent/JP2010077136A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000511535A (ja) * | 1996-05-22 | 2000-09-05 | ユニバーシティー オブ アルベルタ | 2型ケモカイン結合蛋白質およびそれらの使用方法 |
Non-Patent Citations (3)
Title |
---|
JPN4007017474, Microb. Pathog., 1998, 25, p.33−41 * |
JPN4007017475, Microb. Pathog., 1994, 17, p.347−353 * |
JPN4007017476, J. Gen. Virol., 1995, 76, p.1109−1115 * |
Also Published As
Publication number | Publication date |
---|---|
US7101559B2 (en) | 2006-09-05 |
JP2004522427A (ja) | 2004-07-29 |
WO2002046214A3 (en) | 2002-09-26 |
DE60128950T2 (de) | 2008-02-28 |
DE60128950D1 (de) | 2007-07-26 |
CA2428097A1 (en) | 2002-06-13 |
AU1572702A (en) | 2002-06-18 |
JP4472252B2 (ja) | 2010-06-02 |
WO2002046214A2 (en) | 2002-06-13 |
ES2287192T3 (es) | 2007-12-16 |
JP2009227686A (ja) | 2009-10-08 |
DK1339737T3 (da) | 2007-10-15 |
EP1339737B1 (en) | 2007-06-13 |
US20040038203A1 (en) | 2004-02-26 |
PT1339737E (pt) | 2007-09-03 |
ATE364625T1 (de) | 2007-07-15 |
EP1339737A2 (en) | 2003-09-03 |
AU2002215727B9 (en) | 2008-02-21 |
AU2002215727B8 (en) | 2008-02-21 |
AU2002215727B2 (en) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Morrison et al. | Sequence and localization of a partial cDNA encoding the human alpha 3 chain of type IV collagen. | |
US20150139999A1 (en) | Interferon antagonists, antibodies thereto, and associated methods of use | |
JP2010077136A (ja) | 新規免疫修飾性タンパク質およびその有用な態様 | |
JP2001513629A (ja) | ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 | |
US8268331B2 (en) | Nucleic acid molecules and polypeptides for immune modulation | |
AU2002215727A1 (en) | Immunomodulatory protein derived from the yaba monkey tumor virus | |
EP1834960A2 (en) | Immunomodulatory protein derived from the yaba monkey tumor virus | |
AU7598900A (en) | Therapeutic uses of m3 polypeptide | |
AU2002211744A1 (en) | Nucleic acid molecules and polypeptides for immune modulation | |
EP1383883A2 (en) | Asthma-associated snps around microsatellite marker d2s308 and identification of human prolyl-oligopeptidase-dpp10 | |
CA2248144C (en) | Horse endothelin-b receptor gene and gene products | |
US20030165902A1 (en) | Haplotypes of the F2R gene | |
AU2008200257A1 (en) | Nucleic acid molecules and polypeptides for immune modulation | |
WO2007049359A1 (ja) | 糖代謝制御方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100514 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100614 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100929 |